Status:
COMPLETED
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Lead Sponsor:
Sanofi
Conditions:
Advanced Breast Cancer
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor a...
Eligibility Criteria
Inclusion
- Diagnosis of breast cancer
- Evidence that cancer has spread beyond its original location or has come back and cannot be removed by surgery
- No more than one prior treatment for advanced disease
- Her2 positive status
- Adequate liver and kidney function
- No remaining severe harmful effects to prior treatments
Exclusion
- Certain heart condition
- Pregnant Women
- History of another cancer except some skin cancers and cervical cancer
- Taking other treatments for your cancer at the time you enter the trial
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00387907
Start Date
October 1 2006
End Date
March 1 2008
Last Update
May 5 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Malvern, Pennsylvania, United States, 19355